NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing botulinum toxin products for use in aesthetic and therapeutic
indications, today announced that the company will participate in the
2016 Wells Fargo Securities Healthcare Conference in Boston, MA.
Revance management is scheduled to present on Wednesday, September 7 at
Interested parties can access the live audio webcast for both of these
conferences from the Investor Relations section of the company's website
The webcast replay will be available after the conclusion of the live
presentation for approximately 30 days.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is committed to
the advancement of remarkable science. The company is developing a
portfolio of products for aesthetic medicine and underserved therapeutic
specialties, including dermatology and neurology. Revance's science is
based upon a proprietary TransMTS® peptide technology, which when
combined with active drug molecules, may help address current unmet
needs. Revance's initial focus is on developing daxibotulinumtoxinA, the
company's highly purified botulinum toxin, for a broad spectrum of
aesthetic and therapeutic indications, including facial wrinkles and
muscle movement disorders. The company's lead drug candidate,
DaxibotulinumtoxinA for Injection (RT002), is currently in development
for the treatment of glabellar lines and cervical dystonia and has the
potential to be the first long-acting neurotoxin. The company holds
worldwide rights for all indications of RT002 injectable and RT001
topical and the pharmaceutical uses of the TransMTS technology platform.
More information on Revance may be found at www.revance.com.
"Revance Therapeutics", TransMTS®, "Remarkable Science Changes
Everything", and the Revance logo are registered trademarks of Revance
View source version on businesswire.com: http://www.businesswire.com/news/home/20160830005821/en/
Jeanie Herbert, 714-325-3584
Ami Bavishi, 212-213-0006
Nadine Tosk, 504-453-8344
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media